

# Alzheimer's disease (AD) - Pipeline Insight, 2020

<https://marketpublishers.com/r/A021C43BD993EN.html>

Date: November 2020

Pages: 130

Price: US\$ 3,000.00 (Single User License)

ID: A021C43BD993EN

## Abstracts

This report can be delivered to the clients within 5 Business Days

DelveInsight's, "Alzheimer's Disease (AD) – Pipeline Insight, 2020," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer's Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Alzheimer's Disease (AD) Understanding

#### Alzheimer's Disease (AD): Overview

Alzheimer's Disease (AD) is a slowly progressive brain disease that begins many years before symptoms emerge. It is the most common cause of dementia, accounting for an estimated 60% to 80% of cases. The hallmark pathologies of Alzheimer's disease are the accumulation of the protein fragment beta-amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons. These changes are accompanied by the death of neurons and damage to brain tissue. On the basis of severity, this degenerative disease can be classified as mild, moderate, and severe.

### Symptoms

Alzheimer's disease is a progressive condition therefore the symptoms get worse over time. Memory loss is a key feature, and this tends to be one of the first symptoms to develop. Other symptoms are:

Cognitive deficits.

Problems with recognition

Problems with spatial awareness

Problems with speaking, reading, or writing

Later symptoms include impaired communication, disorientation, confusion, poor judgment, behavioral changes and, ultimately, difficulty speaking, swallowing and walking.

As the disease progresses, neurons in other parts of the brain are damaged or destroyed.

## Diagnosis

A diagnosis of Alzheimer's Disease (AD) is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Means of diagnosing AD include clinical diagnosis which is usually made during the mild stage of the disease, Lumbar puncture, and Imaging studies.

## Treatment

Treatment for Alzheimer's Disease (AD) includes options that may reduce the symptoms and help improve the quality of life. The U.S. Food and Drug Administration (FDA) has approved two types of medications — cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda) to treat the cognitive symptoms. Other non-pharmacological therapies are also used with the goal of maintaining or improving cognitive function, the ability to perform activities of daily living or overall quality of life.

## Alzheimer's Disease (AD) Emerging Drugs Chapters

This segment of the Alzheimer's Disease (AD) report encloses its detailed analysis of

various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Alzheimer's Disease (AD) Emerging Drugs

### BAN2401: Eisai

BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble A $\beta$  protofibrils. BAN2401 selectively binds to neutralize and eliminate toxic A $\beta$  protofibrils that are thought to be a causative factor for Alzheimer's Disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer's disease pursuant to an agreement concluded with BioArctic in December 2007.

### Gantenerumab: Hoffmann-La Roche

Gantenerumab is an investigational therapy designed to bind more specifically to aggregated forms of beta-amyloid and remove beta-amyloid plaques. Gantenerumab was originally developed by Chugai Pharmaceuticals, which is now part of Hoffmann-La Roche. This treatment is administered as an injection under the skin, is now being developed by Hoffmann-La Roche in collaboration with MorphoSys.

Further product details are provided in the report

## Alzheimer's Disease (AD): Therapeutic Assessment

This segment of the report provides insights about the different Alzheimer's Disease (AD) drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in Alzheimer's Disease (AD)

There are approx. 100+ key companies which are developing the therapies for Alzheimer's Disease (AD). The companies which have their Alzheimer's Disease (AD)

drug candidates in the most advanced stage, i.e. phase III include, Eisai.

## Phases

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Alzheimer's Disease (AD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Alzheimer's Disease (AD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alzheimer's Disease (AD) therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alzheimer's Disease (AD) drugs.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Alzheimer's Disease (AD) R&D. The therapies under development are focused on novel approaches to treat/improve Alzheimer's Disease (AD).

In December 2019, BioArctic announced the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401. The research collaboration with Eisai is in addition to the existing development and commercialization agreement for BAN2401. This new

collaboration is intended to further characterize the unique binding profile of BAN2401.

## Alzheimer's Disease (AD) Report Insights

Alzheimer's Disease (AD) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Alzheimer's Disease (AD) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Alzheimer's Disease (AD) drugs?

How many Alzheimer's Disease (AD) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alzheimer's Disease (AD)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alzheimer’s Disease (AD) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Alzheimer’s Disease (AD) and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Eisai

Biogen

Changchun Huayang High-tech Co. Ltd.

Hoffmann-La Roche

vTv Therapeutics

AZTherapies

Cerecin

Neurotrope

Lyndra

AC Immune

INmune Bio

Cassava Sciences

EIP Pharma

Neuraly

AB Science

Cortexyme

Anavex Life Sciences

Athira Pharma

Time Therapeutics

Prilenia Therapeutics

Denali Therapeutics Inc.

## Key Products

BAN2401

Elenbecestat (E2609)

Octohydroaminoacridine Succinate

Gantenerumab

Azeliragon (TTP488)

ALZT-OP1

AZT-211

Tricaprilin

Bryostatin-1



Donepezil/memantine extended release

ACI-3024

INB03

Sumifilam

Neflamapimod

Pegylated exenatide

Masitinib

Atuzaginstat

Blarcamesine

NDX-1017

Bromocriptine

Pridopidine

DNL788

## Contents

- Introduction
- Executive Summary
- Alzheimer's Disease (AD): Overview
  - Causes
  - Mechanism of Action
  - Signs and Symptoms
  - Diagnosis
  - Disease Management
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Alzheimer's Disease (AD) – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
  - Alzheimer's Disease (AD) companies' collaborations, Licensing, Acquisition -Deal
- Value Trends
- Alzheimer's Disease (AD) Collaboration Deals
  - Company-Company Collaborations (Licensing / Partnering) Analysis
  - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
  - Comparative Analysis
- BAN2401: Eisai
  - Product Description
  - Research and Development
  - Product Development Activities
- Mid Stage Products (Phase II)
  - Comparative Analysis
- Bryostatin-1: Neurotrope
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report

**Early Stage Products (Phase I)**

Comparative Analysis

**INB03 - INmune Bio**

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

**Pre-clinical and Discovery Stage Products**

Comparative Analysis

**AZT-211: AZTherapies**

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

**Inactive Products**

Comparative Analysis

**Alzheimer's Disease (AD) Key Companies****Alzheimer's Disease (AD) Key Products****Alzheimer's Disease (AD)- Unmet Needs****Alzheimer's Disease (AD)- Market Drivers and Barriers****Alzheimer's Disease (AD)- Future Perspectives and Conclusion****Alzheimer's Disease (AD) Analyst Views****Alzheimer's Disease (AD) Key Companies****Appendix**

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Alzheimer's Disease (AD)
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Alzheimer's Disease (AD)
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Alzheimer's disease (AD) - Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/A021C43BD993EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A021C43BD993EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970